Effects of rotigotine transdermal system on non-motor symptoms in Parkinson’s disease: an overview

References

• Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in PD. J. Neurol. Sci. 289(1–2), 81–88 (2010).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Schapira AH et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov. Disord. 21(7), 916–923 (2006).
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C et al.; PRIAMO study group. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov. Disord. 24(11), 1641–1649 (2009).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 5(3), 235–245 (2006).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 8(5), 464–474 (2009).
   PubMed Web of Science ®Google Scholar
• Benito-León J, Cubo E, Coronell C. Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov. Disord. 27(2), 211–218 (2012).
   PubMed Web of Science ®Google Scholar
• Lemke MR, Fuchs G, Gemende I et al. Depression and Parkinson’s disease. J. Neurol. 251( Suppl. 6), VI/24–27 (2004).
   Web of Science ®Google Scholar
• Sakakibara R, Kishi M, Ogawa E et al. Bladder, bowel, and sexual dysfunction in Parkinson’s disease. Parkinsons Dis. 2011, 924605 (2011).
   PubMed Web of Science ®Google Scholar
• Richy F, Gunn A, Makaroff L, Gervasoni C. Gastrointestinal disorders in Parkinson’s disease: prevalence and health outcomes in a US claims database. J. Parkinsons Dis. 1(1), 65–74 (2011).
   PubMedGoogle Scholar
• Martinez-Martin P, Schapira AH, Stocchi F et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov. Disord. 22(11), 1623–1629 (2007).
   PubMed Web of Science ®Google Scholar
• Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin. Neuropharmacol. 11(6), 512–519 (1988).
   PubMed Web of Science ®Google Scholar
• Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov. Disord. 16(3), 507–510 (2001).
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson’s disease. Mov. Disord. 13(6), 895–899 (1998).
   PubMed Web of Science ®Google Scholar
• Friedman J, Friedman H. Fatigue in Parkinson’s disease. Neurology 43(10), 2016–2018 (1993).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Arnulf I et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74(11), 924–931 (2010).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J. Am. Geriatr. Soc. 48(8), 938–942 (2000).
   PubMed Web of Science ®Google Scholar
• Global Parkinson’s Disease Survey (GPDS) Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov. Disord. 17(1), 60–67 (2002).
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov. Disord. 26(3), 399–406 (2011).
   PubMed Web of Science ®Google Scholar
• Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J. Neurol. Neurosurg. Psychiatry 69(3), 308–312 (2000).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR. The dopaminergic basis of sleep dysfunction and non motor symptoms of Parkinson’s disease: evidence from functional imaging. Exp. Neurol. 216(2), 247–248 (2009).
   PubMed Web of Science ®Google Scholar
• Chaudhuri K, Surmann E, Boroojerdi B, Moran K, Ghys L, Friedman J. Association between motor and nonmotor symptoms in patients with Parkinson’s disease: a post hoc analysis of the Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine (RECOVER) study. Neurology 76, A175 (2011).
   Web of Science ®Google Scholar
• Swick TJ, Surmann E, Boroojerdi B. Association between early morning motor symptoms and nocturnal sleep disturbance in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study. Neurology 76, A175 (2011).
   Web of Science ®Google Scholar
• Bassetti CL. Nonmotor disturbances in Parkinson’s disease. Neurodegener. Dis. 8(3), 95–108 (2011).
   PubMed Web of Science ®Google Scholar
• Jenner P. The rationale for the use of dopamine agonists in Parkinson’s disease. Neurology 45(3 Suppl. 3), S6–S12 (1995).
   PubMed Web of Science ®Google Scholar
• Deleu D, Northway MG, Hanssens Y. An evidence-based review of dopamine receptor agonists in the treatment of Parkinson’s disease. Saudi Med. J. 23(10), 1165–1175 (2002).
   PubMed Web of Science ®Google Scholar
• Steiger M, Jost W, Grandas F, Van Camp G. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review. J. Neural. Transm. 116(2), 179–191 (2009).
   PubMed Web of Science ®Google Scholar
• Baldwin CM, Keating GM. Rotigotine transdermal patch: a review of its use in the management of Parkinson’s disease. CNS Drugs 21(12), 1039–1055 (2007).
   PubMed Web of Science ®Google Scholar
• Boroojerdi B, Wolff HM, Braun M, Scheller DK. Rotigotine transdermal patch for the treatment of Parkinson’s disease and restless legs syndrome. Drugs Today (Barc.) 46(7), 483–505 (2010).
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Levodopa for the treatment of Parkinson’s disease. N. Engl. J. Med. 359(23), 2468–2476 (2008).
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin. Ther. 34(4), 966–978 (2012).
   PubMed Web of Science ®Google Scholar
• Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord. 24(10), 1468–1474 (2009).
   PubMed Web of Science ®Google Scholar
• Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol. Scand. 100(3), 163–167 (1999).
   PubMed Web of Science ®Google Scholar
• Naidu Y, Logishetty K, Martin A et al. Efficacy of apomorphine infusion on mood and depression aspects of nonmotor symptoms in advanced Parkinson’s disease. Parkinsonism Relat. Disord. 15( Suppl. 2), S130 (2009).
   Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Antonini A et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J. Parkinsons Dis. 1(2), 197–203 (2011).
   PubMedGoogle Scholar
• Benbir G, Guilleminault C. Pramipexole: new use for an old drug–the potential use of pramipexole in the treatment of restless legs syndrome. Neuropsychiatr. Dis. Treat. 2(4), 393–405 (2006).
   PubMedGoogle Scholar
• Nashatizadeh MM, Lyons KE, Pahwa R. A review of ropinirole prolonged release in Parkinson’s disease. Clin. Interv. Aging 4, 179–186 (2009).
   PubMed Web of Science ®Google Scholar
• Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson’s disease. Expert Opin. Pharmacother. 10(4), 677–691 (2009).
   PubMed Web of Science ®Google Scholar
• Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn. Schmiedebergs Arch. Pharmacol. 379(1), 73–86 (2009).
   PubMed Web of Science ®Google Scholar
• Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl Acad. Sci. USA 95(18), 10734–10739 (1998).
   PubMed Web of Science ®Google Scholar
• Parsey RV, Oquendo MA, Ogden RT et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11] WAY100635 positron emission tomography study. Biol. Psychiatry 59(2), 106–113 (2006).
   PubMed Web of Science ®Google Scholar
• Singh M, Schwartz TL. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr. Dis. Treat. 8, 123–130 (2012).
   PubMed Web of Science ®Google Scholar
• Schmid DA, Wichniak A, Uhr M et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 31(4), 832–844 (2006).
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M et al.; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov. Disord. 26(1), 90–99 (2011).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in Parkinson’s disease. J. Neurol. 245( Suppl. 1), S15–S18 (1998).
   Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov. Disord. 22(13), 1901–1911 (2007).
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Abe K et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 73(19), 1584–1591 (2009).
   PubMed Web of Science ®Google Scholar
• Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ. Reliability and validity of the Beck depression inventory in patients with Parkinson’s disease. Mov. Disord. 21(5), 668–672 (2006).
   PubMed Web of Science ®Google Scholar
• Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J. Neurol. 245( Suppl. 1), S10–S14 (1998).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Pal S, DiMarco A et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 73(6), 629–635 (2002).
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kohnen R, Hogl B et al. Parkinson’s disease sleep scale–validation of the revised version PDSS-2. Mov. Disord. 26(4), 644–652 (2011).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Antonini A et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: Post hoc analysis of RECOVER. Parkinsonism Relat. Disord. 19(7), 660–665 (2013).
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9(6), 573–580 (2010).
   PubMed Web of Science ®Google Scholar
• Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J. Neurol. 253(5), 601–607 (2006).
   PubMed Web of Science ®Google Scholar
• Rektorová I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur. J. Neurol. 10(4), 399–406 (2003).
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J. Neuropsychiatry Clin. Neurosci. 17(2), 214–220 (2005).
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov. Disord. 26( Suppl. 3), S42–S80 (2011).
   PubMed Web of Science ®Google Scholar
• Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 11(2), 58–65 (2000).
   PubMed Web of Science ®Google Scholar
• Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS Drugs 17(13), 965–973 (2003).
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA et al.; EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14), 1108–1115 (2007).
   PubMed Web of Science ®Google Scholar
• Czernecki V, Schüpbach M, Yaici S et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov. Disord. 23(7), 964–969 (2008).
   PubMed Web of Science ®Google Scholar
• Ceballos-Baumann A, Häck HJ. Rotigotine transdermal patch in combination therapy for Parkinson’s disease–observations in routine clinical practice. Curr. Med. Res. Opin. 27(10), 1899–1905 (2011).
   PubMed Web of Science ®Google Scholar
• Giladi N, Fichtner A, Poewe W, Boroojerdi B. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J. Neural. Transm. 117(12), 1395–1399 (2010).
   PubMed Web of Science ®Google Scholar
• Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol. Urodyn. 23(7), 689–696 (2004).
   PubMed Web of Science ®Google Scholar
• Christmas TJ, Kempster PA, Chapple CR et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2(8626–8627), 1451–1453 (1988).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch. Neurol. 64(5), 676–682 (2007).
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68(16), 1262–1267 (2007).
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 6(6), 513–520 (2007).
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov. Disord. 22(16), 2398–2404 (2007).
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Bremen D et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin. Neuropharmacol. 29(2), 61–67 (2006).
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2(2), 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Heetun ZS, Quigley EM. Gastroparesis and Parkinson’s disease: a systematic review. Parkinsonism Relat. Disord. 18(5), 433–440 (2012).
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphine. Ann. Neurol. 33(5), 490–493 (1993).
   PubMed Web of Science ®Google Scholar
• Martinez-Castrillo JC, Vela L, Del Val J, Alonso-Canovas A. Nonmotor disorders and their correlation with dopamine: can they be treated by currently available methods? Neurologist 17(6 Suppl. 1), S9–S17 (2011).
   Google Scholar
• Trenkwalder C, Kies B, Dioszeghy P et al. Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: results from a 1-year, open-label extension of the RECOVER study. Basal. Ganglia 2, 79–85 (2012).
   Google Scholar
• Antonini A, Bernardi L, Calandrella D, Mancini F, Plebani M. Rotigotine transdermal patch in the management of Parkinson’s disease (PD) and its night-time use for PD-related sleep disorders. Funct. Neurol. 25(1), 21–25 (2010).
   PubMed Web of Science ®Google Scholar
• Scheller D, Dürmüller N, Peyron G. Continuous administration of rotigotine enhances wakefulness but may deepen sleep in 6-OHDA lesioned rats. Presented at: 2nd World Parkinson Congress. Glasgow, UK, 28 September–1 October 2010.
   Google Scholar
• Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology 61(10), 1418–1420 (2003).
   PubMed Web of Science ®Google Scholar
• Leeman AL, O’Neill CJ, Nicholson PW et al. Parkinson’s disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br. J. Clin. Pharmacol. 24(5), 637–643 (1987).
   PubMed Web of Science ®Google Scholar
• Reichmann H, Cooper J, Rolfe K, Martinez-Martin P. Sleep duration and “on” time during different periods of the day and night in patients with advanced Parkinson’s disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis. 354760 (2011).
   Google Scholar
• Morita A, Okuma Y, Kamei S et al. Pramipexole reduces the prevalence of fatigue in patients with Parkinson’s disease. Intern. Med. 50(19), 2163–2168 (2011).
   PubMed Web of Science ®Google Scholar
• Abe K, Takanashi M, Yanagihara T, Sakoda S. Pergolide mesilate may improve fatigue in patients with Parkinson’s disease. Behav. Neurol. 13(3–4), 117–121 (2001).
   PubMed Web of Science ®Google Scholar
• Ghys L, Surmann E, Whitesides J, Boroojerdi B. Effect of rotigotine on sleep and quality of life in Parkinson’s disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin. Pharmacother 12(13), 1985–1998 (2011).
   PubMed Web of Science ®Google Scholar
• Schestatsky P, Kumru H, Valls-Solé J et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69(23), 2162–2169 (2007).
   PubMed Web of Science ®Google Scholar
• Ha AD, Jankovic J. Pain in Parkinson’s disease. Mov. Disord. 27(4), 485–491 (2012).
   PubMed Web of Science ®Google Scholar
• Brefel-Courbon C, Payoux P, Thalamas C et al. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov. Disord. 20(12), 1557–1563 (2005).
   PubMed Web of Science ®Google Scholar
• Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J. Neurol. Neurosurg. Psychiatry 78(10), 1140–1142 (2007).
   PubMed Web of Science ®Google Scholar
• Dellapina E, Gerdelat-Mas A, Ory-Magne F et al. Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov. Disord. 26(1), 153–157 (2011).
   PubMed Web of Science ®Google Scholar
• Park A, Stacy M. Dopamine-induced nonmotor symptoms of Parkinson’s disease. Parkinson’s Dis. 485063 (2011).
   Google Scholar
• Weintraub D, Koester J, Potenza MN et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67(5), 589–595 (2010).
   PubMed Web of Science ®Google Scholar
• Hassan A, Bower JH, Kumar N et al. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat. Disord. 17(4), 260–264 (2011).
   PubMed Web of Science ®Google Scholar
• Auyeung M, Tsoi TH, Tang WK et al. Impulse control disorders in Chinese Parkinson’s disease patients: the effect of ergot derived dopamine agonist. Parkinsonism Relat. Disord. 17(8), 635–637 (2011).
   PubMed Web of Science ®Google Scholar
• Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson’s disease. CNS Drugs 25(3), 203–212 (2011).
   PubMed Web of Science ®Google Scholar
• Swick TJ. Parkinson’s disease and sleep/wake disturbances. Parkinson’s Dis. 205471 (2012).
   Google Scholar
• Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA. Excessive daytime sleepiness and its risk factors in incident Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 84(2), 233–234 (2013).
   PubMed Web of Science ®Google Scholar
• Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch. Neurol. 61(1), 97–102 (2004).
   PubMedGoogle Scholar
• Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov. Disord. 18(6), 659–667 (2003).
   PubMed Web of Science ®Google Scholar
• Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: a prospective, open-label extension study. Parkinsonism Relat. Disord. 18(5), 488–493 (2012).
   PubMed Web of Science ®Google Scholar
• Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14(6), 540–545 (1991).
   PubMed Web of Science ®Google Scholar